|
|
Article: Cambridge, Mass., Drug Maker, British Firm Team Up on Bowel-Disorder Medicine.
- Article from:
- Knight Ridder/Tribune Business News
- Article date:
- April 25, 2002
CopyrightCOPYRIGHT 2002 Knight-Ridder/Tribune Business News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News
Apr. 25--Biogen Inc. yesterday said it would partner with a British company to develop and market a drug, CDP 571, that is in late stages of human testing for Crohn's disease, an inflammatory bowel disorder.
The deal with Celltech Group PLC bolsters Biogen's pipeline, putting the Cambridge company in position to have four products on the market by 2005. The two companies will share the costs of developing the product and will jointly market the drug.
Biogen has long relied on its huge-selling multiple sclerosis drug, Avonex, to drive profits and growth. As Avonex faces ...